PD47-03 FAMILY HISTORY AND INCREASED RISK OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL

Abstract

You have accessJournal of UrologyProstate Cancer: Epidemiology & Natural History III1 Apr 2017PD47-03 FAMILY HISTORY AND INCREASED RISK OF CLINICALLY SIGNIFICANT PROSTATE CANCER IN THE PLCO CANCER SCREENING TRIAL Adrien Bernstein, Ron Golan, Jonathan Shoag, Brian Dinerman, and Jim C. Hu Adrien BernsteinAdrien Bernstein More articles by this author , Ron GolanRon Golan More articles by this author , Jonathan ShoagJonathan Shoag More articles by this author , Brian DinermanBrian Dinerman More articles by this author , and Jim C. HuJim C. Hu More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2363AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A family history (FH) of prostate cancer (CaP) is associated with an increased risk of CaP. However, it remains unclear how this association impacts the need for screening. The aim of this study is to evaluate the impact of FH of the diagnosis of clinically significant CaP in a large national cohort. METHODS The study included 73,045 men from the control and screening arms of the Prostate Lung Colorectal and Ovarian (PLCO) trial, which had complete information regarding FH and CaP diagnosis. Incidence of clinically significant cancer (CS; intermediate or high risk disease) was compared by FH. The relationship between number of relatives diagnosed and age at CaP diagnosis was evaluated. Multivariable logistic regression was used to estimate odds rato (OR) and 95% confidence intervals (CI). RESULTS FH was associated with a significantly increased risk of both CaP [OR 1.6, (95% CI 1.5-1.8)] and CS-CaP [OR 1.7 (95% CI 1.5-1.8), respectively]. Furthermore, the impact of FH on CS-CaP increased with the number of family members with CaP; for participants with one relative, the OR was 1.6 (95% CI 1.5-1.8); for those with multiple relatives, the OR increased to 2.2 (95% CI 1.6-3.2). Men with younger relatives with prostate cancer (< 65 vs ≥65 years) were more likely to be diagnosed with CS-CaP, [OR 1.6, (95%CI 1.3-2.0)]. FH, number of affected relatives and age of relatives remained significant on multivariable analysis controlling for ages, race, smoking history, history of BPH, marital status employment status and study arm. CONCLUSIONS Detailed FH, including the number of relatives and relatives′ age of at diagnosis significantly affect a man′s risk of CS-CaP and should be taken into consideration during individualized counseling about the frequency and intensity of screening. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e897 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Adrien Bernstein More articles by this author Ron Golan More articles by this author Jonathan Shoag More articles by this author Brian Dinerman More articles by this author Jim C. Hu More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...